some info10 Apr 2014 09:35
recent news..e-Therapeutics is maintaining momentum in its development programme for lead anti-cancer drug ETS2101 (dexanabinol). Interim data from the Phase Ia UK solid tumours trial have confirmed ETS2101 is safe and well tolerated up to doses of 22mg/kg. This, coupled with initial observations that suggest a potential anti-tumour effect, supports the decision to continue the trial up to the maximum tolerated dose (MTD) and to further explore potential efficacy. Data from this extension, as well as from the ongoing US Phase I/II glioma trial and a newly initiated healthy volunteer study of an oral formulation, will provide comprehensive data to inform next development steps.